



TAIWAN

Your Best Partner in Asia

Taiwan Pavilion
Booth NO. 743 & 843

2023 BIO International Convention
June 5-8, 2023

Taiwan, Your Best Partner in Asia!

As the center of Asia-Pacific region, Taiwan is not only a crucial link between Europe, America, Japan and the emerging Asia-Pacific markets, but also a preferred location for multinational companies to establish their regional headquarters.

In addition, Taiwan's government actively promotes the precision health industry to realize interdisciplinary collaboration to reach the goal, a vision of whole-life health, in 2030.



1st

HEALTH CARE INDEX
(NUMBEO 2023)

3rd

BEST DESTINATION
for EXPATRIATES
(INTERNATIONS 2022)

COMPREHENSIVE BIO-CLUSTERS

NORTHERN TAIWAN

- DRUGS (DISCOVERY, BIOLOGICS, PHARMACEUTICS)
- MEDICAL DEVICES (DIAGNOSTICS, MEDICAL ELECTRONICS, IVD, MEDICAL IMAGING)

CENTRAL TAIWAN

- DRUGS (PHARMACEUTICS, VACCINES)
- MEDICAL DEVICES (REHABILITATION DEVICES, MINIMAL INVASIVE SURGICAL DEVICES)

SOUTHERN TAIWAN

- DRUGS (API)
- MEDICAL DEVICES (IMPLANTABLE DEVICES, MINIMAL INVASIVE SURGICAL DEVICES)
- HERBAL MEDICINES, FUNCTIONAL FOODS, ANIMAL BREEDING AND VACCINES

6th
3rd in Asia

ECONOMIC FREEDOM INDEX
(HERITAGE FOUNDATION 2022)

7th
3rd in Asia



WORLD COMPETITIVENESS RANKING (IMD 2022)

Exhibit Hall Floor Plan



Exhibit Hall Floor Plan

Delegate No.



Content

Biologics	Page	No.
ACRO Biomedical Co., Ltd.	01	21
ARCE Therapeutics, Inc.	02	32
EARNING Co., Ltd.	03	35
EirGenix, Inc.	04	01
eXCELL Biotherapeutics Inc.	05	15
LumiSTAR Biotechnology, Inc.	06	06
OBI Pharma, Inc.	07	12
PharmaEssentia Corp.	08	18
PrecisemAb Biotech Co., Ltd.	09	31
Taiwan Tashah Biotech Co., Ltd.	10	23
Biotech (incl. Agriculture)	Page	No.
Adimmune-Animmune	11	14
BRIM Biotechnology, Inc.	12	11
Formosa Pharmaceuticals, Inc.	13	12
Health Ever Bio-Tech Co., Ltd.	14	05
PhytoHealth Corporation	15	20
Simpson Biotech Co., Ltd.	16	03
Suntec Medical, Inc.	17	33
TLC BioSciences	18	22
T-E Meds, Inc.	19	34
Xantho Biotechnology Co., Ltd.	20	33

Content

Contracted Service(incl. CDMO)	Page	No.
Agricultural Technology Research Institute	21	13
Amaran Biotechnology, Inc.	22	09
CancerFree Biotech Ltd.	23	16
Formosa Laboratories, Inc.	24	02
Mycenax Biotech Inc.	25	19
Praexisio Taiwan Inc.	26	29
Hospital/Research Institution	Page	No.
Research Center for Emerging Viral Infections, Chang Gung University	27	07
China Medical University	28	04
China Medical University Hospital	29	28
Show Chwan Healthcare System Center for MedTech Commercialization	30	27
Taipei Veterans General Hospital & ASUSTeK Computer Inc.	31	27
Global Industry Platform of National Taiwan University System	75	-
Medical Device	Page	No.
Altek Biotechnology	32	06
Chang Gu Biotechnology Co., Ltd.	33	11
MedFluid Co., Ltd.	34	26
Neurobit Technologies Co., Ltd.	35	29
PlexBio Co., Ltd.	36	10
Smart Surgery technology Co., Ltd.	37	30
SoundJet Medical, Inc.	38	37
WeMED Biotech Inc.	39	37

Content

Precision Health	Page	No.
Big Data Mobile Company	40	10
CatchGene Co., Ltd.	41	36
CytoAurora Biotechnologies, Inc.	42	36
JelloX Biotech Inc.	43	34
Micronbrane Medical Co., Ltd.	44	30
Small Molecule Drug	Page	No.
AnHorn Medicines Co., Ltd.	45	32
ImmunAdd Inc.	46	31
Zih Yuan Tang Biotechnology Co., Ltd.	47	19
Smart Health	Page	No.
AESOP Technology Inc.	48	35
AHEAD Medicine Corporation	49	16
FaceHeart Corporation	50	28
Preteeth AI Co., Ltd.	51	26
Government/Non-Profit Institution	Page	No.
Academia Sinica	52	17
Asia Silicon Valley Development Agency	53	-
Biomedical Translation Research Center, Academia Sinica	54	17
Central Taiwan Science Park	55	-
China Productivity Center	56	-
Council of Agriculture	57	-

Content

Government/Non-Profit Institution	Page	No.
Department of Academia-Industry Collaboration and Science Park Affairs, National Science and Technology Council	58	-
Development Center for Biotechnology	59	39
Hsinchu Science Park Bureau, National Science and Technology Council	60	-
Industrial Development Bureau, Ministry of Economic Affairs	61	-
Industrial Technology Research Institute	62	38
Medical and Pharmaceutical Industry Technology and Development Center	63	24
Ministry of Health and Welfare	64	-
National Health Research Institutes	65	25
National Science and Technology Council	66	-
Office of Science and Technology Policy National Science and Technology Council	67	-
Southern Taiwan Science Park Precision Health Cluster	68	-
Startup Island TAIWAN	69	-
Taipei City Government	70	-
Taipei Exchange	71	-
Taiwan Bio Industry Organization	72	08
Taiwan External Trade Development Council	73	-
Taiwan Stock Exchange	74	-



Main Products / Services / Pipelines & Platforms

- ABCcolla® Collagen Matrix - The porous collagen biomaterial absorbs wound exudates and maintains an moist environment conducive to healing.
- ABCcolla® Bone Graft - It is intended for filling and augmentation of bone voids or gaps during orthopedic and dental surgeries. It facilitates cell attachment and improves bone regeneration and neovascularization.
- ABCcolla® Collagen Ophthalmic Matrix - It is intended for cornea transplantation in replacement of human donated cornea.
- ACROTERM™ Tissue & Organ Scaffolds - Native collagen scaffolds derived from porcine tissues and organs, decellularized by supercritical CO₂ extraction technology. All scaffolds retain their native ECM structures and are biocompatible for stem cell culture and tissue engineering research.
- ACROTERM™ Tissue & Organ Scaffold Powders - Native collagen scaffold powders derived from porcine tissues and organs, decellularized by supercritical CO₂ extraction technology. All scaffold particles retain their native ECM structures, suitable for 3D bioprinting research purposes.

Business Interests

- Distribution (代理/經銷)
- ODM/OEM (委託設計/製造/生產)
- R&D Collaboration (研發合作)
- Licensing (授權)

Contact Information

Name Ni Wang
Position Marketing Specialist
Tel +886 (7) 695 5569 Ext. 228
Email niwang@acrobiomedical.com



Cell Technology Platforms

Three unique cell technology platforms, named DashCAR®, MaxCAR®, and OneCAR®, for CAR immune cell therapy.

Main Product

- ARD103 (CLL-1 DashCAR®-T)
- Indication: blood cancer relapsed/refractory AML
- Target: Human C-type lectin-like molecule 1 (CLL-1)
- The median of positive expression rate of CLL-1 in tumor cells of all patients was 85.2% (range 50.2%-97.6%).
- CLL-1 is expressed on both blasts and leukemia stem cells, but not on hematopoietic stem cells.

Product Features

- Ultrafast DashCAR® bioprocess in 3 days
- High productivity with > 80% CAR+
- Engineered cells conserving stemness > 80%
- High specificity without off-target issues
- Safe with limited hematotoxicity
- Proved efficacy & durability in animal models
- IND-enabling targeted IND in Q4/2023

Business Interests

- CLL-1 CAR-T product early-entry to the market
- Seek partners to collaborate the U.S. and global clinical development
- Seek out-licensing opportunity

Contact Information

Name Chien-Tsun Kuan
Position President / CEO
Tel +919 961 6163 (U.S.) +886 909 576 846 (Taiwan)
Email ct_kuan@ARCEtherapeutics.com

Name Li-Ming Lu
Position Project Manager/ Business Development
Tel +886 920 787 815 (Taiwan)
Email liming_lu@arcetherapeutics.com

Main Products / Services / Pipelines & Platforms

- Preclinical Comparative Oncology CRO
- Translational oncology by integrating veterinary clinical oncology into preclinical comparative oncology
- Use engineered tumoroid, tumor explant-on-a-chip derived from canine biopsy samples to investigate profound mechanism inside the tumor-immune-microbiota microenvironment (TIMM).
- Novel Techniques of spatial biology including 3D Tissue imaging and transcriptomics to TIMM.
- Comparative oncology trial on dogs with naturally occurring tumors on an interdisciplinary platform of scientist, engineer, veterinarian and doctor.
- The first-in-Taiwan “Center of Comparative Medicine and Research” to one-stop serve with basic (lab animal), comparative (dog and large animal), clinical (human) study and trial with university and teaching hospitals.

Business Interests

- Preclinical development of drug discovery and medical device
- Collaborative R&D
- Contracted preclinical R&D, and comparative oncology trial
- Translational marketing of veterinary clinical product and service
- Investment

Contact Information

Name Miko Wen
Position CEO
Tel +886 952 129931
Email earningmed@gmail.com



Main Products / Services / Pipelines & Platforms

- Biologics CDMO in Mammalian & Microbial Expression Systems
- Small-scale to Commercial-scale GMP Manufacturing
- Biosimilars Co-development & Licensing
- US FDA Inspected & EIR Received
- Taiwan FDA & Japan PMDA Approved

Business Interests

- Biologics CDMO- mAb, bispecific antibody, ADC, recombinant protein/peptide, plasmid DNA, RNA and viral vector
- Biologics CMO- commercial GMP Production
- Multiple SUBs- 200L, 1000L, 2000L & 4000L
- M&A - Biologics CDMO or CRO

Contact Information

Name Albert C. Lin
Position Business Development Director
Tel +886 930 060 588
Email albert.chlin@eirgenix.com



Main Products / Services / Pipelines & Platforms

Xenogeneic cell-based products for cancer immunotherapy

Business Interests

For human and pet health, our mission is to design, develop and deliver the constructive xenogeneic cell immunotherapy to improve cancer patients' outcomes.

Contact Information

Name Chih-Rong Shyr
Position CEO
Tel +886-963133934
Email chshyr@gmail.com



Main Products / Services / Pipelines & Platforms

iPSC technology and live cell imaging platform- A platform monitoring cellular characteristics as indicators of drug efficacy or cellular functionality for high throughput/content screening.

Applications:

Our Drug Discovery Pipelines:

- Neurodegenerative Diseases (Alzheimer's and Parkinson's)
- Anti-fibrosis
- Anti-viral agents

Our iPSC Cell Therapy Pipelines:

- Parkinson's Disease
- Renal Fibrosis
- Solid Tumors (iPSC-NK)

Business Interests

- Out-Licensing
- Collaborative R&D for drug discovery
- Clinical collaboration on iPSC-based cell therapies

Contact Information

Name Chih-Chuan Su
Position Business Development Manager
Tel +886 935 877 816
Email chih-chuan.su@lumistar.com.tw



Main Products / Services / Pipelines & Platforms

OBI Pharma, Inc., is a Taiwan biopharmaceutical company publicly-listed on the Taipei Exchange (TPex ticker: 4174). OBI's mission is to develop and license novel therapeutic agents for unmet medical needs against cancer targets such as Globo Series (incl. Globo H, SSEA3, SSEA4) and AKR1C3. Globo Series and AKR1C3 are highly expressed in cancers of unmet need including Breast, Ovarian, Gastric, Lung, Liver Prostate and Esophageal. The company's novel first-in-class oncology portfolio includes:

- Adagloxad Simolenin (formerly OBI-822; Globo H cancer vaccine)
- OBI-833 (Globo H cancer vaccine)
- OBI-999 (Globo H ADC)
- OBI-3424 (small-molecule prodrug targeting AKR1C3 enzyme)
- R992 (Trop-2 ADC)

Business Interests

- OBI is seeking out-licensing opportunities to expedite the clinical development of our pipeline products. OBI is also looking to in-license novel anti-cancer therapies to compliment and strengthen our pipeline.

Contact Information

Name Kevin Poulos
Position Chief Commercial Officer
Tel +619 537 7698 Ext. 102
Email kpoulos@obipharmausa.com



Main Products / Services / Pipelines & Platforms

- BESREMI® (ropeginterferon alfa-2b)
- Proprietary PEGylation Platform

Business Interests

- General Collaboration
- Licensing

Contact Information

Name Derek Yuan

Position Business Development Director

Email derek_yuan@pharmaessentia.com



Main Services / Platforms

Antibody drugs lead to serious side effects because they cannot distinguish disease tissue from normal tissue and which limits their application. The Antibody Lock™ allows antibody drugs to take effect only in diseased areas to solve systemic toxicity and can revive clinically failed antibody drugs due to safety concerns and expand the market of undruggable antigens for pharma and antibody-drug conjugates (ADC) companies.

Features

- Higher masking ability and removal ability
- Low immunogenicity
- Prevention of anti-drug antibody binding
- Prolonged serum half-life

Lead Product

PSM101, the lead candidate for head and neck cancer and colorectal cancer treatment, will complete stable cell clone generation in 2023 and the non-human primate side effect test in 2024-Q2.

Partnering

Through (1) co-development of Lock-antibodies and (2) customized Antibody Lock design service, PrecisemAb licenses out Lock-antibodies to global pharma for conducting further clinical trials.

Business Interests

- Cooperation Partners of Lead Product-PSM101
- Strategic Partners of ADC
- Customized Antibody Lock Design Service
- Out-licensing of Lock-antibodies

Contact Information

Name LiChen Yen
Position BD Manager
Tel +886 (7) 311 1577
Email lichen.yen@precisemab.com



Main Products / Services / Pipelines & Platforms

- Rubber Stopper (Chlorobutyl/Bromobutyl/Nitrile/Laminated ETFE&PTFE)
- Infusion Discs (Polyisoprene)
- Syringe Plungers(Single Use Syringe Plunger Stoppers/Prefilled Syringe Plunger Stoppers)
- Cartridge Plunger
- Cartridge Combiseal(From 1ml to 3ml Mono layer & Bi-layer)

Business Interests

Collaborative R&D, CDMO, Distribution, Long-Term Partnership, Product Supply Agreement

Contact Information

Name Kurt Wu
Position Sales Manager / Project Manager
Tel +886 (3) 538 4686 Ext.11
Email kurtwu@shengzou.com



Main Products / Services / Pipelines & Platforms

- Season Influenza Vaccine
- CMO & CDMO Service (PFS fill/finish, Bacular Virus Insect Cell System, Egg Base System, Cell Culture System)
- Animal Vaccine Development

Business Interests

- CMO & CDMO Service
- Animal Vaccine Development

Contact Information

Name Albert Hung
Position President of Animmune Deputy Chief Operating officer of Adimmune
Tel +886 922 655 461
Email albert_hung@adimmune.com.tw



Main Products / Services / Pipelines & Platforms

BRM421

- First-in-class treatment for Dry Eye Disease (DED)
- Safe and effective therapy with fast relief
- Expect to obtain the result of a US Phase 3 trial by the end of 2023

BRM424

- Orphan drug for Neurotrophic Keratitis
- US Phase 2 initiated

PDSP platform

- Pigment Epithelium-Derived Factor (PEDF) derived Short Peptide (PDSP) platform
- Repairs damaged tissues by promoting stem cell proliferation and differentiation
- Early-onset potential in various disease animal models
- Low immunogenicity, no endotoxin risk, and high pharmaceutical stability

Business Interests

Out-licensing, in-licensing, co-development, investment

Contact Information

Name Yichun Maria Chen
Position VP of Business Development
Tel +886 (2) 2659 8586
Email yichun.chen@brimbiotech.com

Name Yilun Chiang
Position Business Development Manager
Tel +886 (2) 2659 8586
Email yilun.chiang@brimbiotech.com



Leading Pipeline Assets:

APP13007

- Clobetasol Propionate Ophthalmic Nanosuspension for Inflammation and Pain after Ocular Surgery
- Less-frequent administration: BID x 2 weeks; Increased patient compliance
- Convincing efficacy: Rapid clearance of inflammation and progression to pain-free
- Enhanced formulation: Superior homogeneity for more comfortable administration
- Compelling safety profile: No ocular toxicity; Low incidence of IOP elevation

TSY-0110

- ADC biosimilar of Kadcyca (T-DM1)
- TSY-0110 is in late-preclinical development stages, planning for CTA filing
- Seeking interested parties for regional / global licensing or co-development

Proprietary Platform:

APNT Nanoparticle Formulation Platform

- Operates on the principle of particle size reduction to improve dissolution and bioavailability, with lower risk of contamination
- Free of solvents and harsh additives
- Stable formulation / Increased Bioavailability / Enhanced Safety Profile / Increased IP value of asset
- Optimized for oral, inhaler, topical, and ophthalmic administration routes

Business Interests

- Seeking out-licensing opportunities for leading pipeline assets.
- Seeking co-development partner for Proprietary Platform.

Contact Information

Name Wayne Wei
Position Director, Business Development
Tel +886 (2) 2755 7659
Email waynewei@formosapharma.com



Main Pipelines

New Drug Product Boreso[®] for BPH/LUTS.

Business Interests

- Out-Licensing
- Collaborative R&D

Contact Information

Name Alex Chen
Position Business Development Director
Tel +886 (2) 2732 5205 Ext. 20
Email alex.c@hebiotech.com



Main Products / Services / Pipelines & Platforms

Commercial status

- PG2[®]Lyo. Injection is used for the treatment of cancer-related fatigue.
- Oraphine[®] (nalbuphine HCl soft capsule) is used for the relief of moderate to severe acute pain.

Clinical status (Phase II completed)

- PHN031: osteoporosis prevention
- PHN033: diabetic nephropathy
- PG2[®]Lyo.combo therapy: cancer treatment

Business Interests

- Out-licensing of PG2[®] and Oraphine[®]
- In-licensing of the products related to cancer supportive care, cancer therapy and neurology
- Co-develop inline products in new indications

Contact Information

Name Alison Tsai
Tel +886 (2) 2545 3697 Ext. 2315
Email alison.tsai@phytohealth.com.tw

Name Angel Lee
Tel +886 (2) 2545 3697
Email angellee@maywufa.com.tw



Main Products / Services / Pipelines & Platforms

Small molecular compound for non-alcoholic fatty liver disease (NAFLD)

- Prevent liver oil accumulation (US, CN, TW patents)
- Prevent liver-fibrosis
- Anti-inflammation, anti-oxidation
- improve liver regeneration

1. ANTRODIA CINNAMOMEA EXTRACT (INCI Name), patented skin-whitening, anti-aging, anti-inflammation natural ingredients from fermented medicinal fungus

2. HERPEPTSTM: Patented new recombinant proteins expression & purification platform

- One-step purification using patented starch-binding protein
- Applied to yeast, mammalian cell, E. coli, insect cell etc.
- Self-owned IP-free Pichia pastoris expression vector: methanol-free, antibiotics-marker-free
- Protein expressed: industrial enzymes, cytokines, growth factor etc.
- Already turnkey to US company for industrial enzyme production

3. Dietary supplement Ingredients

- Antrodia cinnamomea mycelia for liver protection & hangover relief
- Fucoidan for metabolic syndrome & Immune booster
- StarchMate® for glycemic index reduction
- Fermented ginseng & Ginsenoside compound K for brain health

4. Natural anti-bacteria & anti-yeast chitosan at 50 ppm

Business Interests

- Out-Licensing
- CDMO for recombinant proteins

Contact Information

Name Cevia Shih
Position Technical Sales Specialist
Tel +886 (3) 396 3466 Ext. 36
Email cevia@simpsonbiotech.com



Main Products (MINC Platform technology)

Suntec is a clinical stage biopharmaceutical company. Its MINC (Multi-target Immune-modulation Nanocomplex) platform generates first in class NME with high efficacy and safety due to.

- Alzheimer's/Parkinson's: 1) deliver high drug dosages (10-100x) to the brain to stop the disease progression, 2) reduce inflammation and edema to the brain, 3) repair damaged neuronal cells to restore patients' cognitive behavior.
- Vaccine: 1) stimulates higher antibody titer, 2) stabilizes RNA/DNA for long term 4-25°C storage.
- Cancer: 1) boosts immunotherapy efficacy and response rates, 2) removes ADR from chemotherapy or immunotherapy.

PIPELINES

- a pipeline of 11 drug candidates for cancers (4), Alzheimer's (6) and Parkinson's (1).
- three clinical stage drugs (STM-001, 002, 003) in 2023 with FDA "breakthrough" designation potentials
- All drugs carry long IP protections (18-19 yrs).

Business Interests

- **Out-license:** Out-license STM-001, 002, 003 after phase I clinicals and obtaining FDA "breakthrough" designations.
- **Co-development:** All pipeline drugs are open to co-development.
- **Fund raising:** Series A fundraising to support clinicals.

Contact Information

Name Isaac Cheng (鄭鈞霆)
Position Vice President, Research
Tel +886 909 277 680
Email isaac.cheng@suntecmedical.com



Main Products / Services / Pipelines & Platforms

TLC BioSciences is a clinical-stage specialty pharmaceutical company developing novel nanomedicines that maximize the potential of its proprietary LipAD[®] lipid-assembled drug delivery platforms, with a focus on treatment options for patients with orthopedic disorders and traumas.

LipAD[®] Platforms:

- BioSeizer[®] - sustained release technology for biologics and/or small molecules
- NanoX[®] - tissue-targeted liposomal delivery with an ionic gradient for active drug loading, proven in 2 approved drugs

Pipeline:

- TLC599 (osteoarthritis pain)
- TLC590 (postsurgical pain)
- TLC399 (macular edema)
- TLC178 (advanced malignancies / soft tissue sarcoma)
- Ampholipad[®] (systemic fungal infections)

Business Interests

- Out-Licensing
- Collaborative R&D

Contact Information

Name Ms. Lindsey Yang
Position Specialist, President's office
Tel +886 (2) 2655 7377
Email lindsey@tlcbio.com



Main Platforms / Products

- **ADC/ARC Platforms:** Site-specific conjugation with high homogeneity, high Drug-to-Antibody Ratio (DAR), enzyme-free process, produce soluble and stable ADC/ARC drug candidates.
- **Drug Bundles:** Proprietary payload/linker designs. Multiple copies of payload molecules are conjugated to a “Multi-Arm Linker” , and connected to antibody through a controlled site-specific conjugation process. Payload/linker units are prepared in modules and assembled to customized bundles. Various cytotoxic drug bundles, e.g., Lenalidomide, MMAE, MMAF, SN38, DXd, DM1, PDB drug bundles and radionuclide bundles, e.g., DOTA bundles, are available. Assembled easily. Dual-payload designs are applicable.
- **TE-1146:** Anti-CD38 ADC with lenalidomide bundles for multiple myeloma treatment. TE-1146 shows superior anti-tumor efficacy, good safety and stability, planning for IND filing between 2024-2025.
- **TE-1132:** Anti-CA19-9 ARC with DOTA bundles for pancreatic cancer treatment & diagnosis. TE-1132 shows strong anti-tumor efficacy, 100% overall survival rate in tumor bearing mice models, planning for IND filing in 2025.

Business Interests

- Series A fundraising
- Out-licensing ADC/ARC technology platforms to biotech, pharma, and CDMO
- Out-licensing TE-1146 ADC (anti-CD38 for multiple myeloma treatment) and TE-1132 ARC (anti-CA19-9 for pancreatic cancer diagnosis / treatment)
- Collaborations in research and development of ADC/ARC platforms

Contact Information

Name Kun-Po Li
Position Associate Director of External Collaboration and Clinical Development
Tel +886 (2) 2651 2268
Email bd@temeds.com



Main Products

GM-XANTHO

- Non-steroidal topical new drug for treating atopic dermatitis
- Effective in treating and preventing inflammatory skin conditions
- Low side effects
- Phase 2a clinical trial data available
- Available in large quantities with PIC/S GMP specifications

Business Interests

GM-XANTHO is available for out-licensing with rights in drug development and commercialization.

Contact Information

Name William Wu
Position Project Manager
Tel +886 (2) 2655 7790
Email research@xanthobio.com



Main Products / Services / Pipelines & Platforms

Animal Study

- Certification: OECD-GLP and AAALAC
- Efficacy: Acute myocardial ischemia (AMI), Wound healing, Dental defect, Pulmonary fibrosis study, and Customized animal models
- Safety testing: Skin toxicity testing, Medical devices biocompatibility

Biosafety Testing Services

- Certification: OECD-GLP, TFDA-GLP, and PIC/S GMP
- Service: Biological Safety Testing and Virus Validation

SPF Pig Tissue Supply

- Tissues: SPF pig skin and bone
- Certification: ISO 13485:2016 according to ISO 22442-1:2015 and ISO 22442-2:2015
- Application: Production of collagen and bone meal

Business Interests

Collaborative R&D. We offer animal study can evaluate efficacy, toxicity study using pig model and bio-safety service to biotechnology companies. We want to contact the exhibitors help to screen potential candidate and accelerate new drug development.

Contact Information

Name Chi-Yu Yang
Position Chief
Tel +886 (37) 585 816
Email chiyu@mail.atri.org.tw



Main Products / Services / Pipelines & Platforms

[Saponin Adjuvant]

Amaran Biotech provides cGMP grade saponin adjuvant QS-21 of high purity.

[CDMO Service for Drug Development]

- Drug Substance Contract Manufacturing:
 - Specialized in carbohydrate synthesis, conjugation of different modalities such as glycoprotein production, the downstream purification of protein and natural product, and lyophilization.
- Drug Product Aseptic Fill and Finish in Vials, PFS, and Cartridge:
 - Full robotic, aseptic-filling system (Cytiva Vanrx SA25) in Taiwan.
 - The filling line features low filling loss (less than 50 mL) and high filling accuracy and precision, particularly for those at low fill volumes (down to 0.1 mL)
 - Specialized for biologics products of high value, and those adopting gene and cell therapy (CGT) platform for rare disease, genetic disease or used as precision/ personalized medicine.
- Stability Study & Analytical Science Services
- Sourcing & Consultation Services

Business Interests

- CDMO service and Global Partnership for the cGMP manufacturing of critical substances and injectable products.
- Collaborative R&D for new chemical/biologics entity entering clinical trial.

Contact Information

Name Ryan Lo
Position Director, Business Development & Regulatory Affairs
Tel +886 912 470 665
Email ryan.lo@amaran.com.tw



Main Products / Services / Pipelines & Platforms

- Our service-Ex Vivo Avatar (called "E.V.A.") combines liquid biopsy and in vitro tumoroid culture as an avatar technology.
- Decision support system for oncologists and cancer patients.
- Comprehensive service in multiple oncology terms, such as cell therapy, cancer vaccine and new drug development.

Business Interests

- Joint research in drug discovery programs.
- Look for strategic partners in the U.S., such as CROs, pharmaceutical companies and academic institutes.
- Product development collaborations.

Contact Information

Name Sherry Chen
Position CPO
Tel +886 (2) 2732 2701
Email Yihuan.chen@cancerfree.io



Main Products / Services / Pipelines & Platforms

GMP and GDP compliance

- API development and manufacturing services
- Fermentation API development and manufacturing services
- Peptide development and manufacturing services
- ADC development and manufacturing services
- ADC payload-linker screening platform
- Formulation development
- Injectable filling services
- Packing, labelling, and delivering services
- Regulatory services
- API and injectable products sales and licensing-out

Business Interests

- Out-licensing injectable products.
- API, fermentation, peptide, ADC, and injectable CDMO/CMO services

Contact Information

Name Tom Tseng
Position Manager of FDF&CDMO Service in Marketing & Sales
Tel +886 (3) 324 0895 Ext. 277 / +886 966 582 336
Email tomtseng@formosalab.com



Main Products / Services / Pipelines & Platforms

Mycenax is a 20-year bio-CDMO providing services for recombinant proteins, enzymes, mAb, BsAb, antibody-drug conjugates (ADC), and cell therapy products.

- Druggability
- Cell Line Development
- Process Development
- Analytical Method Development
- Formulation Development
- GMP Production
- Aseptic Fill and Finish

Business Interests

- Mycenax is a fully dedicated bio-CDMO.
- We also offer an open platform of novel technologies from our collaborators, such as ADCC enhancing technology (CHO pharma) and site-specific linkers for ADC, to enhance our customers' projects in terms of product quality and efficacy.

Contact Information

Name Lin-Lu Tseng, Ph.D.
Position Associate BD Manager
Tel +886 (3) 667 0880 Ext. 5115
Email linlu.tseng@mycenax.com.tw



Main Products / Services / Pipelines & Platforms

- Computational Biology Service – Protein Molecular Dynamics Simulations Enhanced Drug Design
- Drug Screening Platform: DRDOCK (Drug Repurposing DOcking with Conformation-sampling and pose re-ranKing)
- High-Speed Alignment Small Molecule Search Engines: SmChem
- NGS-based Connectivity Map (CMAP) techniques
- Computing Resource Integration Scheduling System: Axtasy (DGX A100 TAsk manager and queuing SYstem)
- Automated Pathogenic Mutation Classifier: HOLMES

Business Interests

- Out-Licensing, Consultancy, Cross-Industry Alliance with System Integrator, Extended Bioinformatics Team to CDMO or pharma.

Contact Information

Name Yi-Yun Cheng
Position Medical Affairs Director
Tel +886 912 735 289
Email anny.cheng@praexisio.com.tw



Main Products / Services / Pipelines & Platforms

RCEVI can provide customized one-stop solution for virus research before preclinical trial.

- **Service items:** virus detection, virus isolation, antiviral or vaccine efficacy evaluation, high-throughput antiviral screening, etc.
- **In vitro model:** plaque assay, plaque reduction assay, neutralization assay, hemagglutination inhibition (HI) assay, RT-qPCR, ELISA, cytotoxicity, etc.
- **In vivo model:** Transgenic mouse model for virus challenge, in vivo imaging system (IVIS), etc.
- **Pathogens:** Respiratory viruses (e.g., coronavirus, influenza virus, RSV, parainfluenza virus and others), Enteroviruses (e.g., EV-A71, EV-D68, coxsackievirus and others), Arbovirus (e.g., dengue virus, ZIKA virus and others), Enteric viruses (e.g., norovirus, rotavirus and others)
- **Facilities:** BSL-2, ABSL-2, BSL-3, ABSL-3
RCEVI also has a strong research team devoting to virus research, the representative publications and patents are listed at the following link: <https://rceviweb.wixsite.com/rcevi>

Business Interests

RCEVI offers a range of customized services, such as antiviral testing, validation of diagnostic kits, and vaccine/drug development. We have launched various products in Taiwan via out-licensing agreements and collaborate with research centers in Chang Gung University for high-quality R&D, emphasizing their core competencies in all the tests of viruses.

Contact Information

Name Shin-Ru Shih | Kuei-Ching Hsiung
Position Director/Distinguished Professor | Postdoctoral Fellow
Tel +886 (3) 211 8800 Ext.5497 | +886 (3) 211 8800 Ext. 3041
Email rsrshih@mail.cgu.edu.tw | kchsiung@gap.cgu.edu.tw



Main Products / Services / Pipelines & Platforms

- CAR001- new generation CAR-T therapy offers an off-the-shelf solution that utilizes BiTE-secreting CAR- $\gamma\delta$ T as a dual targeting strategy for the treatment of solid tumors
- INSP platform nanotechnology targets tumors and thrombosis for precision delivery of a variety APIs including generics, biologics and nucleic acids to improve therapeutic efficacy and quality of life. The lead candidate INSP003 (polysaccharidic docetaxel) has been applied to FDA for pre-IND consultation.
- Olprogel – is bone implant fixation media with high biocompatibility. Apply Olprogel during implantation to stabilize implants and induce better healing.
Petcongell – is an injectable hydrogel which combined with anticancer drugs. Petcongell applied to malignant tumors can achieve sustained drug release and reduce wound infection.

Business Interests

Ever Supreme Bio Technology

Ever Supreme is focused on advancing breakthrough therapies through our two technological platforms: immune cell therapy and stem cell therapy drug development. We are actively seeking out-licensing, joint venture, and related business opportunities with

INSP Nanotechnology Platform - An Innovative Targeted Therapy for Cancer and Cerebrovascular Disease

Our translational team has a primary focus on the development of precision nanomedicine from nano-based chemotherapeutics to nucleic acid drug. We are seeking global collaboration on out-licensing opportunities, co-development, CDMO and CRO partnerships to translate the lead drug INSP003.

Olproheal Biomimic

We are a biomedical start-up group striving to develop quality biomimetic medical innovations. With our own laboratory and medical device factory, international collaborative R&D and CDMO are direction of our business cooperation.

Contact Information

Name Anita WU
Position Project Manager
Tel +886 (4) 2205 3366 Ext. 2513
Email anitawu0606@gmail.com



Main Products / Services / Pipelines & Platforms

Taiwan Life AID- Heart-saving starting before arrival

- The "Symptoms to balloon (S2B)" after a heart attack significantly impacts myocardial viability. CMUH has developed a pre-hospital STEMI detection system based on 12-lead ECG, which aims to enable patients with STEMI to receive cardiac catheterization as soon as possible.
- This system has now been implemented and used by 52 fire brigades in Taichung City and Nantou County. Over 700 ambulance patients have used the system, resulting in the diagnosis of 32 STEMI patients.
- Over 80% of STEMI patients can complete STEMI diagnosis within 10 minutes.
- Emergency medical technicians can achieve the shortest time from contact to blood vessel perfusion before arrival at the hospital, only requiring 92 minutes.
- It helps STEMI patients receive triage within 10 minutes of symptom onset, with the system results with as high as 99.5% accuracy, providing a reliable clinical diagnosis.

Business Interests

- In-/Out-Licensing: USFDA
- Collaborative R&D
- Data exchange cooperation
- Knowledge sharing and technical support

Contact Information

Name Kai-Cheng Hsu
Position Director
Tel +886 910 616 960
Email D35842@mail.cmuh.org.tw



Main Services

Bridging clinical niche and technology gap

We empower early-stage innovation in the most efficient way

Services

- **Prototyping**

Through patient journey mapping and bio-design process, we help medical experts on prototyping for rapid testing and iteration, resulting in customized products that meet unique clinical needs. .

- **MedTech StartHub**

By bringing together entrepreneurs, investors, and industry experts, we help facilitate efficient and effective resource allocation for early-stage companies with the resources they need to succeed.

- **Counseling**

Our services include expert guidance on design thinking, patents, regulations, clinical trials, and fundraising, providing comprehensive support to help early-stage startups to achieve their goals..

Business Interests

- **Collaborative R&D**

With 9 hospitals and 1 most advanced surgery training center in Asia, we are interested in international collaborative R&D projects.

- **CDMO**

In partnership with Taiwan ICT industry, we bridge manufacturing resources for early-stage innovations.

Contact Information

Name Anya Lee
Position Project Manager
Tel +886 975 611 095
Email anya.show@gmail.com



Main Products / Services / Pipelines & Platforms

ASUS Miraico

- Medical coding AI assistant that automatically recommends ICD-10 codes in real-time by analyzing free-text medical records, optimizing hospital operational efficiency, accelerating revenue cycle, and improving reimbursements.

ASUS Lumos

- Real-World Data (RWD) Platform built with a structured research database to offer EMR Search and Cohort Study to analyze and generate medical insights efficiently.

ASUS xHIS Platform

- Next-generation HIS platform, empowered by AI and cloud technologies, establishes a common data model and standard development toolkits to enable modularization and customization framework to create a developer-friendly ecosystem for the trend towards smart medicine.
- These products are developed by AICS (ASUS Intelligent Cloud Services), ASUSTeK Inc.

Business Interests

VGHTPE has interest in B2B collaboration with companies serving 200 or more hospitals. ASUS AICS is keen to collaborate with AI innovators and platform developers to create strong technology partnerships and continue providing revolutionary healthcare solutions.

Contact Information

Name Miranda Wu | Ying-Chou Sun M.D.
Position Product Director | Deputy Director, Medical AI Development Center
Tel +886 (2) 2894 3447 Ext. 21263 | +886 (2) 2875 7835
Email Miranda_Wu@asus.com | ijsun@vghtpe.gov.tw



Main Products / Services / Pipelines & Platforms

Wearable injectors for subcutaneous self-administration

- Compatible with various primary containers including standard vials and customized cartridges
- Reusable unit designed to be environmentally-friendly
- Easy to use, one button push for injection
- Wide range of delivery volume up to 20 mL
- Programmable to customize injection settings
- Continuous wearing for days

Business Interests

Our company specializes in the design and manufacturing of wearable injectors for pharmaceutical and biotech companies

Contact Information

Name Yu-hsuan Chang
Position Senior Manager
Tel +886 (3) 578 4567 Ext. 6219
Email yuhsuanchang@altek.com.tw



Main Products

EVA Expandable Vertebral Augmentation System

"EVA" Expandable Vertebral Augmentation System" is a new treatment for the vertebral compression fracture (VCF), which is different from the existing treatment methods: vertebroplasty and Kyphoplasty. The "EVA Expandable Vertebral Augmentation System" can effectively restore the vertebral body height by placing and expanding the implant in the vertebral body, prevent leakage of bone cement during injection, and keep providing strength and stability to the vertebral body.

Business Interests

- Out-Licensing
- Market agency authorization
- Acquisition investment

Contact Information

Name Morgan Lin
Position R&D Director
Tel +886 921 875 679
Email service@cgbio.net



Main Products

We have total solutions for portable diagnostics laboratory based on our patented microfluidics technology.

Product 1: NAST

Incorporated with a portable analyzer, this patented gravity-driven microfluidic cartridge was developed to acquire rapid antimicrobial susceptibility testing (AST) result as fastest as 6 hours directly using collected specimen. NAST is able to avoid drug resistance in clinics with accurate antibiotic medication reports, removing the need of professionals and central laboratory.

Product 2:O-in

O-in is an all-in-one molecular diagnostics system, providing one-shot genetic testing to identify 6 multiple target genes within 25 mins. The patented pneumatic membrane-type microfluidic modules enable the cartridge to automatically conduct bead-based DNA/RNA purification, precise liquid handling and RT-PCR/LAMP process upon one single click on the screen. MedFluid is committed to offer precision diagnostics without the limitation of space, time and costs.

Business Interests

- Direct import, sales to distributors or hospital (Human and veterinary market)
- Strategic partners (Local device and reagents GMP suppliers)
- CDMO using Integrated Lab-on-chip platform (Liquid biopsy, protein detection, veterinary diagnostics, food safety, Pesticide residue detection, Environmental test)

Contact Information

Name Bon Lee
Position CEO
Tel +886 (3) 658 7974
Email info@medfluid.com.tw



Main Products / Services / Pipelines & Platforms

- NeuroSwift - Basic dizziness/vertigo assessment & Preoperative and postoperative evaluation of Strabismus
- NeuroSwift Pro - Advanced dizziness/vertigo assessment
- eyeForm - Myopia progression analysis & recommended treatment

Business Interests

- Hospitals
- Distributors

Contact Information

Name Travis Yang
Position CEO
Tel +886 (2) 2771 0618
Email travisyang@neurobittech.com



Main Products / Services

PlexBio Co., Ltd. founded in 2010, is dedicated to the development of innovative, high-performance, and diversified in vitro diagnostic reagents and instrument platforms with our core technology, Precision Image Code (π Code®) MicroDiscs. PlexBio are committed to the delivery of accurate, simple, and rapid tests for high-quality innovative products and services in the market, and to be a major player in the global IVD market.

Main Products:

- **Sample Preparation Systems:**

IntelliPrep® TRIO 240 Sample Preparation System, Stellar96 Nucleic Acid Extraction System

- **IntelliPlex® Multiplexing π Code Systems:**

PlexBio® 100 Fluorescent Analyzer, IntelliPlex® 1000 π Code Processor

- **IntelliPlex® Multiplexing Assays:**

IntelliPlex® Lung Cancer Panel, IntelliPlex® Single Gene Mutation Kits, IntelliPlex® SARS-CoV-2 Detection Test Kit, IntelliPlex® HPV Genotyping Kit

Services:

- CDMO Services
- Technology Licensing

Business Interests

- Distributor
- RUO/ LDTs
- KOL Collaborations
- CDMO Services
- Technology Licensing

Contact Information

Name Judy Ma
Position Business Development Manager
Tel +886 (2) 2627 5878 Ext. 191
Email judy.ma@plexbio.com



Main Products / Services / Pipelines & Platforms

Smart Surgery Technology offers two main products:

- **Minimally invasive surgery AI image recognition system**
The Minimally Invasive Surgery AI Image Recognition System is an innovative medical technology that can help doctors perform minimally invasive surgery more accurately, improve the success rate and safety of the surgery, and further improve the treatment efficacy for patients.
- **Smart Surgery Minimally Invasive Surgery Education Platform**
Smart Surgery Technology has developed a "Smart Surgery Minimally Invasive Surgery Education Platform" for medical professionals to learn independently through VR simulations. The content includes video lessons, instrument operation simulations, and surgical simulations that allow users to learn minimally invasive surgical techniques and become familiar with surgical instruments. The platform only requires a laptop and VR glasses, making it accessible from anywhere.

Business Interests

Our technology is licensed by Taipei Medical University.

Contact Information

Name Yu-Chieh Lee
Position CEO
Tel +886 (2) 2732 2500
Email service@smartsurgerytek.com



Main Products / Services / Pipelines & Platforms

- SoundJet Medical develops an innovative ultrasonic thrombolytic device to treat patients with pulmonary embolism (PE) and deep vein thrombosis (DVT).
- The core technology of SoundJet Medical is ultrasonic vortex, which dissolves blood clots in a very efficient and safe way so as to achieve high performance in thrombolysis.

Business Interests

- Out-Licensing
- Collaborative R&D
- CDMO
- CRO

Contact Information

Name Chun-Yen Lai
Position CEO
Tel +886 921 357 366
Email chunyen.lai@gmail.com



Main Products / Services

- iMET – a device to positioning the distal screw holes of an interlocking nail (also known as the intramedullary (IM) nail) in an interlocking nailing procedure. Compares with the use of C-arm to target the distal screw holes, iMET uses visible light, and is faster, more accurate, and poses no radiation exposure problems to the patient and to the surgeons.
- iKypho – a device used in percutaneous vertebroplasty (PVP) or percutaneous kyphoplasty (PKP) surgeries. iKypho uses the pressure differential technique to guide the injected bone cement from one side of the vertebra to the other side. It can prevent bone cement leakage and provide more homogeneous cement filling inside the vertebra.

Business Interests

WeMED is seeking for distributors, collaborative sales, out-licensing, or collaborative R&D opportunities.

Contact Information

Name WoeiChyn Chu, Ph.D
Position Founder & Chairman
Tel +1 (707) 294 0727 | +886 935 623 789 | +886 (2) 26974518
Email woeichyn@berkeley.edu | woeichyn@gmail.com



Main Products / Services / Pipelines & Platforms

B.D Mobile specializes in digital health solutions. B.D Mobile mobile ECG analysis platform provides assisted ECG interpretation through artificial intelligence.

Pipelines & Platforms

Users can perform online ECG feature analysis, disease identification, data management, process management, and provide customized reports through our platform. The goal is to simplify the modern ECG measurement process, speed up the efficiency of ECG diagnosis, and provide more accurate ECG-assisted interpretation.

Services

- The ECG analysis platform has achieved AI arrhythmia interpretation, AI anti-noise, traditional process simplification, automated analysis and other innovations.
- Through the platform integration of all tools and services, the efficiency and accuracy of ECG interpretation have been greatly improved.

Business Interests

- In-/Out-Licensing
- Collaborative R&D
- Pharmacist
- Agent
- Health Management Center
- Insurance Company

Contact Information

Name Joyce
Position COO
Tel +886 953 030 836
Email linliyu1230@gmail.com



Main Products / Services / Pipelines & Platforms

- iCATCHER 12 Automated Nucleic Acid Purification System
- (Series) Nucleic Acid Purification Kits

Business Interests

Finding distributors or dealers

Contact Information

Name Alex Lee
Position General Manager
Tel +886 (2) 2228 6585
Email alexlee@catchgene.com



Main Products / Services / Pipelines & Platforms

Cell Reveal Serials: Medical Diagnosis Markets

- **Cell Reveal: Rare Cell Capture and Analysis System**
A new single cell capture, isolation and analysis technology that utilizes a fully automated operating platform to standardize the detection process, and through AI tech, quickly and effectively identify the target cell.

Cell Aurora Serials: Benefit to CDMO Industry

- **Cell Aurora 0: Single-Cell Droplet & Separation**
Using solenoid valve to control flow cytometry, single living cells are used for cell separation to achieve the purpose of rapid cell sorting.
- **Cell Aurora 1: High-Throughput Single-Cell Isolation**
Combined with photoelectric control and wafer modification for high-throughput single-cell separation applications.

Business Interests

- Market expansion
- Looking for strategy partner
- Looking for distributor
- CDMO

Contact Information

Name Chung-Er Huang
Position CEO
Tel +886 (3) 610 5568 Ext. 8888
Email ce.huang@cytoaurora.com



Main Products / Services / Pipelines & Platforms

3D Digital Pathology Imaging Analysis

- Capturing cells and biomarkers with spatial distribution
- Discovering hidden biomarker signatures (eg. PD-L1, Her2)
- Finding amenable patients for precision therapeutics

Digital Pathology Software with AI-enabled Platform

- Labeling pathology features for quantitative analysis
- Developing tailor-made AI algorithm with domain knowledge
- Serving as digital twin pathology unit for reference labs

Business Interests

- Service package of 3D pathology for new drug development
- System integration for multi-functional digital pathology platform
- Collaborative R&D for clinical diagnosis & investment

Contact Information

Name Margaret Dah-Tsyr Chang
Position Chief Strategy Officer
Tel +011 886 3658 3058
Email sales@jellox.com



Main Products / Services / Pipelines & Platforms

- Devin™ Fractionation Syringe Filter
- Devin™ Microbial DNA Enrichment Kit
- Unison™ Ultralow DNA NGS Library Preparation Kit

Business Interests

Micronbrane Medical is a biotechnology company based in Taiwan. We provide cost-effective, rapid, and accurate pathogen detection solutions for human infections. Our products and technologies make it possible to precisely identify both known and unknown pathogens from any body liquid sample within 24 hours.

Contact Information

Name Igor Dulesov
Position BD Director
Tel +886 (2) 3316 6428
Email igor.dulesov@micronbrane.com



Main Pipelines & Platforms

- Protein degrader for Prostate Cancer
- Protein degrader for Androgenetic Alopecia
- Non-covalent KRAS inhibitor for G12C, G12D, G13D, G12V mutations
- Protein degrader discovery platform open for research collaboration

Business Interests

Out-Licensing, Collaborative R&D

Contact Information

Name Wendy Lin
Position Operations Mgr
Tel +886 921 233 794
Email anhorn01@anhornmed.com



Main Products

Vaccine adjuvants:

- IA-05: a novel synthetic saponin adjuvant that has been designed to mimic the structure of the natural saponin adjuvant QS-21, but with modifications that improve its tolerability, and stability and make it more amenable to large-scale manufacturing with GMP-grade quality.
- IAS-01 (synthetic TLR4 and saponin): a synthetic saponin adjuvant system that contains both a synthetic TLR4 agonist and a saponin adjuvant. It is designed to be immunogenicity equivalent to the existing MPL and saponins liposome-based adjuvant product, but with improved scalability, stability, and tolerability. By combining these two adjuvants, IAS-01 is intended to enhance both the innate and adaptive immune responses to vaccines, leading to stronger and longer-lasting immunity.

Contact Information

Name Pi-Hui Liang
Position Acting CEO
Tel +886 (2) 3366 8695
Email phliang@immunadd.com



資元堂
ZIH YUAN TANG

ZIH YUAN TANG Biotechnology Co., Ltd.



zih-yuan-tang.com

Main Products / Services / Pipelines & Platforms

We have discovered and was awarded US patents a remarkable molecule BAE with the following medicinal applications :

- macular edema (ME).
- wet age-related macular degeneration (wet AMD).
- non-proliferation diabetic retinopathy (NPDR).
- Orally, in the 28-day test of NPDR Indian rhesus monkeys, it was confirmed that it was effective in improving macular leakage, and abnormalities were found 56 days after drug withdrawal.

At present, the pharmacological effects are known, and many studies have been carried out.

BAE effectively treats microvascular leakage in NPDR, avoiding blurred vision or even blindness at the PDR stage.

Business Interests

- We are looking for business partners, hoping to have more funds to enter preclinical animal tests and IND; or, Out-Licensing.
- According to the authoritative Grand View Research report: In the NPDR stage, the global market will exceed US 10 billion annually.

Contact Information

Name CHAO-MIN HSU
Position President
Tel +886 (2) 2378 0588
Email jimmy@zih-yuan-tang.com



Main Product

Medigator

AI-powered and evidence-based guidance for immunotherapy

- Proactively analyze medical records to identify appropriate candidates for immunotherapy
- Recommends targeted immunotherapy plans for early, mid and late-stage cancer patients
- Predict individual risk of immune-related adverse events (irAEs) and manage medications
- Tracks and predicts progression, prognosis and the efficacy of immunotherapy
- Organizing evidence-based clinical guidance for immunotherapy
- Better shared decision making with more information

Business Interests

Market expansion, Collaborative R&D

Contact Information

Name Jeremiah Scholl
Position Chief of Product
Tel +1 415 818 0633
Email jeremiah@aesoptek.com



Main Products / Services / Pipelines & Platforms

AI-based cloud platform with fully automated, end-to-end solutions for expert level analyses in :

- Disease classification
- Outcome monitoring
- Quality monitoring of the cell manufacturing process

Business Interests

R&D Partnering, Fundraising

Contact Information

Name K. Karen Lin, Ph.D.
Position VP of Corporate Development and Strategy
Tel +1 510 210 5671
Email karen.lin@aheadmedicine.com



Main Products / Services / Pipelines & Platforms

Connected by AI from Face to Heart

FaceHeart Vitals™ is a contactless AI video-based rPPG solution that empowers everyday devices using a 30-60s selfie video to measure key vital signs, including Heart Rate (HR), Blood Pressure (BP), Oxygen Saturation (SpO2), and Respiratory Rate (RR).

- 100M Images from 3000+ Patients
- FDA Clearance anticipated by Q2 2023
- Medical-Grade Accuracy
- Supports Web & Edge Solutions

Business Interests

FaceHeart provides a cross-platform Software Development Kit (SDK) or Web page for any players who are interested in adopting contactless vital sign measurements as part of their service offerings.

- Hardware Vendors (IDH/ODM/OEM)
- Medical Channels
- Value-added Service Providers
- Smart Health Application/Management
- SmartHealth Service Solution/Platform

Contact Information

Name Marketing Team
Tel +886 (3) 659 1088
Email marketing@faceheart.com



Main Products / Services / Pipelines & Platforms

- AI Front Desk Assistant: Integrate AI to answer phone calls and make appointments directly into the practice management system. We streamline appointment scheduling and reduce the overhead with our customizable language model.
- Preteeth AI Pro: An app for instant smile analysis and smile designs, enhancing the cosmetic dental consultation experience.

Business Interests

- Searching for design partners, including VoIP or practice management system (PMS) company
- Distributor or Selling Agents
- API Integration

Contact Information

Name Bill Chou
Position CEO & Co-founder
Tel +886 988 004 610
Email bill.chou@preteeth.com



Main Services

Academia Sinica promotes the internal integration of research activities in our three Divisions (Mathematics and Physical Sciences, Life Sciences, and Humanities and Social Sciences). We aim to enhance research value through improved planning, implementation, evaluation of long-term projects, applying research findings to technology transfer, engaging with Taiwan's academic community, promoting international cooperation and scholarship, and creating an intellectual environment that benefits scholars.

Business Interests

- Research cooperation
- Technology transfer
- Material Transfer

Contact Information

Name Jing-Fen, Wang
Position Technology Transfer Manager
Tel +886 (2) 2787 2509
Email jingfen@gate.sinica.edu.tw



Main Pipelines & Platforms

Taiwan's Asia Silicon Valley Development Agency (ASVDA) is responsible for coordinating cross-ministerial resources to roll out the Asia Silicon Valley Development Plan 2.0. By "accelerating industrial evolution with AIoT" and "driving next-generation industries with innovation and entrepreneurship," Asia Silicon Valley 2.0 incorporates AI, 5G, and other critical technologies of the digital economy to expand the scope of internet-of-things applications, encourage the exit of AIoT solutions and accelerate the growth and exit of startups to make Taiwan a driving force for digital innovation in Asia.

Contact Information

Name Cassie Chien
Position Manager
Tel +886 (2) 2518 2552
Email cassie@asvda.org.tw



Main Services

Construct a Strong Biotech Ecosystem

- Forge a professional and innovative ecosystem that facilitates new drug discovery, as the creation of a thriving biotechnology industry will ultimately enhance health and welfare of society.

Support innovative biomedical translation research

- Solicit the most promising proposals of projects that seek to translate biomedical technologies.
- Facilitate industry-oriented innovation and multi-disciplinary collaboration in translational medicine, enhancing the competitiveness of new drug development and medical applications from translational research to clinical use.

World-Class Core Facilities

- Accelerate the timeline for translational research and pre-clinical verification of innovative precision by providing researchers with advanced instruments, high-priced equipment, and technical services on disease prevention, detection, diagnosis and treatment.

Incubate Startup Companies

- Incubate companies to push the development of Biologics, Nucleic Acid Drugs & Regenerative Medicine, Smart Healthcare & Precision Medicine, and Botanical Drugs & Small Molecule Drugs.
- Provide one-stop service to support resident companies during R&D stage and subsequent product commercialization.
- Cultivate business talents by constructing training programs on scientific innovation and entrepreneurship.

Business Interests

- Translational medical research, Core facility support, Innovation and incubation center, Smart healthcare, Collaborative Bio cluster / Bio park.

Contact Information

Name Monica Bey | Kenny Huang
Position BioHub Deputy CEO | Project Manager
Tel +886 916 276 021 | +886 (2) 7750 5314
Email monica1014@gate.sinica.edu.tw | kyhuang0815@gate.sinica.edu.tw



<https://www.ctsp.gov.tw/english/00home/home.aspx?v=20>

Main Products / Services

Products

- Medical & Assistive devices
- Vaccines & Drugs
- Dietary supplements
- Advanced agricultural products

Service

- Integrated industrial, academic and medical resources
- Developing new solutions that better support public needs

Business Interests

Collaborative R&D, CDMO

Contact Information

Name I-Jou Chen (Athena)
Position Translator
Tel +886 (4) 2565 8588 Ext.1112
Email Email : ijouchen@ctsp.gov.tw



Main Services

China Productivity Center (CPC), as the executive organizer of the 2023 Taipei City Biotechnology Industry Guidance Program. We are honored to have this opportunity to gather around outstanding biotech and medical companies for Taipei City Government to participate in the world's largest event for the biotechnology industry. By showcasing their latest products and R&D activities at the event, it is our mutual goal to elevate the visibility and discover new opportunities.

Our core business scope:

- Management Consulting
- Government Projects
- Education and Training
- Media Publication
- International Exchange
- Management Knowledge Center

Business Interests

Seeking in-/out-licensing, collaborative R&D, CDMO opportunities for Taiwanese biotechnology and Medicine companies.

Contact Information

Name Sherry Shang
Position Manager
Tel +886 (2) 2698 2989 Ext. 01954
Email 01954@cpc.org.tw



Contact Information

Name Meng-Fang Hsu
Position Specialist
Tel +886 (2) 2312 4058
Email mengfang@mail.coa.gov.tw

Name Hsin-Chuan Huang
Position Associate Researcher
Tel +886 (2) 2312 4018
Email hsinchuanh@mail.coa.gov.tw



Main Services

To enhance innovation and entrepreneurship for academic research

- With the innovation and entrepreneurship programs, the department encourages a deep technology from university to new venture, build a platform like Taiwan Tech Arena (TTA) to drive more corporate with international investors and offers programs for startups to global exhibitions and talent exchanges.

To support academia-industry relationship

- With the Academia-industry collaboration programs, the department encourages businesses to participate in university-based applied research projects, promotes collaboration on highly innovative research projects, establishes rules for co-ownership of research results, and creates alternative models for technology transfer authorization, thus increasing the effectiveness of industry-academia cooperation.

To cultivate industrial talents

- To train S&T talents for high-tech industries, the department provides Ph.D. students with training programs both in the universities and internships for professionals.

To develop of science parks

- The science parks strive for innovation, inclusion, and sustainability. We aim to strengthen the development policies of the science parks, review and revise related regulations, science parks enterprise investment review, talents cultivation and management integration.

Business Interests

- Innovation And Entrepreneurship
- Academia-industry Collaboration
- Startups
- Talent Cultivation

Contact Information

Name Eric Lin
Position Specialist
Tel +886 (2) 2737 7932
Email ericlin72@nstc.gov.tw



Main Products / Services / Pipelines & Platforms

I. Research and development of novel drugs in the following fields

- Biologics R&D service
- Pharmaceuticals drug R&D service
- Pharmacology & drug disposition

II. Integrated business services, including

- Market intelligence and research
- IP protection
- Startups incubation
- Talent cultivation
- Technology valuation and transfer
- International cooperation

Business Interests

Out-Licensing, Collaborative R&D, Spin-off, CDMO Collaboration

Contact Information

Name Jeffrey Ching-Hsu Yang (楊景旭)
Tel +886 (2) 7700 3800 Ext. 5293
Email ch.yang@dcb.org.tw



Main Services

Complete IC industry cluster

- Global top IC industry supply chain in upstream, midstream, and downstream offering cross-domain industry solutions in diversified high-tech sectors, e.g. big data, IoT, AI, biotech, etc.

Brilliant platform for biomedical industries

- Development of cutting-edge medical devices and new drugs, integrating with core research facilities and hospitals, solidifying precision medical treatment industries.

Cradle for new ventures

- Fostering a great environment for innovative ventures and entrepreneurship via terrific mentoring services and supports from surrounding academia, industries, and R&D facilities, together with close ties with global peers.

Top ranking academia and R&D organizations with humanity concerns

- Surrounded with top leading academia and research organizations, providing fruitful talent and research resources.

Superior service quality and efficiency via one-stop services

- The Hsinchu Science Park Bureau offers diversified one-stop services, e.g. company registration, talent cultivation, R&D grants application, factory and land leasing, etc.

Business Interests

- Providing top-tier infrastructure and comprehensive one-stop services.
- Promoting industry-academia R&D collaboration. Creating a cluster of innovative ventures in world arena.
- Creating a cluster of innovative ventures in world arena.

Contact Information

Name Wenhui Chen
Position Officer, Business Promotion Section, Investment Division
Tel +886 (3) 577 3311 Ext. 2229
Email whchen@sipa.gov.tw



Main Mission

- The bureau is in charge of the national industrial development tasks.
- Offer a full range of services according to industrial needs.
- Lead the industry of Taiwan to pursue innovation, upgrading, and enterprise transformation.
- Guide enterprises to strengthen their management system, increase productivity and enhance international competitiveness.
- Assist enterprises to face changes in the overall environment and provide policy subsidies.

Contact Information

Tel +886 (2) 2655 8135
Email services@biopharm.org.tw



ITRI

Industrial Technology
Research Institute

Industrial Technology Research Institute



www.itri.org.tw/english/index.aspx

Main Products / Services / Pipelines & Platforms

- One-Stop Biomedical Services: R&D, Prototyping, GxP Trial Production, Regulation, Licensing
- Innovative Immunotherapeutic Strategies - Novel Designs of TLR9 Agonists for Boosting Cancer Immunotherapy
- Orally Bioavailable AR/AR-V7 PROTAC for the Treatment with Castration-Resistant Prostate Cancer (CRPC)
- Regulation Compliant MSC - Cell Bank and Final Product Manufacturing Technology
- Additive Manufacturing of Biodegradable Iron-Based Materials for Medical Implants

Business Interests

- R&D Collaboration
- CDMO/ CRO
- Out-Licensing
- GxP Trial Production

Contact Information

Email ITRI_BDL@itri.org.tw



財團法人醫藥工業技術發展中心



Main Products / Services / Pipelines & Platforms

- Hot-melt extrusion drug manufacturing technology
- Drug eluting medical devices
- Botanical product development (Small molecule drugs 、 Functional food)
- Stem cells therapy products
- Cell culture medium optimization

Business Interests

- Out-licensing of pharmaceutical technology, including hot-melt extrusion drugs, drug-eluting medical devices, botanical products, and stem cell products, to external parties.
- Collaborative clinical trials for stem cell products and botanical products.
- CDMO services for complex generic drug.

Contact Information

Tel +886 (2) 6625 1166
Email pitdc_p@pitdc.org.tw



Main Products / Services / Pipelines & Platforms

The Ministry of Health and Welfare of the Republic of China (MOHW) is the Executive Yuan ministry responsible and the highest authority for the administration of the public health system, social welfare, affordable and universal health care, hospitals, pharmaceutical, immunization programs, disease prevention, supervision and coordination of local health agencies in Taiwan. The MOHW was originally established on 17 March 1971 as the Department of Health (DOH). The department was upgraded to Ministry of Health and Welfare on 23 July 2013 with the addition from the agencies in the Ministry of the Interior responsible for social welfare following restructuring of the Executive Yuan. The mission of MOHW is to promote the health and well-being of all Taiwan citizens.

Business Interests

The MOHW's diversified responsibilities include health policy planning and promotion, prevention and control of disease, food safety, drug management, social insurance and welfare, relief and protective services.

Contact Information

Name Hsien-yang Lee
Position Researcher, Office of Science and Technology
Tel +886 (2) 8590 7567
Email schsien-yanglee0641@mohw.gov.tw



Main Products / Services / Pipelines & Platforms

- Advance biomedical sciences
- Promote population and individual health
- Forge biotechnology and pharmaceutical development
- Train and cultivate biomedical researchers

Business Interests

R&D Collaboration, Licensing

Contact Information

Name Hua-Hsuan Liang
Position Acting Section Chief
Tel +886 (37) 206 166 Ext. 33206
Email huahsuan@nhri.edu.tw



Main Products / Services / Pipelines & Platforms

The BioMed Commercialization Center(BMCC), funded by the National Science and Technology Council (NSTC), is to provide an integrated platform to overcome the bottleneck found in the development and commercialization of pharmaceuticals and medical devices for academia and industries.

Business Interests

- IP/Tech feasibility and analysis for pharmaceuticals and medical devices
- Prototyping service for pharmaceuticals and medical devices
- Marketing analysis and regulatory compliance support for pharmaceuticals and medical devices
- Accelerate commercialization for pharmaceuticals and medical devices

Contact Information

Name BioMed Commercialization Center
Tel +886 (2) 2652 2677 (Pharmaceuticals);
+886 (3) 658 8760 Ext. 2044 (Medical Device)
Email dcc@biip-dcc.org (Pharmaceuticals);
pcchou@biip-mdcc.org (Medical Device)



Main Products / Services / Pipelines & Platforms

Office of Science and Technology Policy (OSTP), a taskforce of National Science and Technology Council, helps to coordinate the S&T issues of critical national interest.

The main missions of OSTP

- Assist to formulate and review national science and technology (S&T) development policy.
- Assist to organize S&T strategy conferences and handle S&T issues assigned by the Executive Yuan.
- Support strategy analysis, policy planning and coordination for S&T research and industry development.
- Coordinate, integrate and promote cross-ministerial S&T development initiatives.

Contact Information

Name Su Yu Tsai
Position Senior Administrator
Email shuyutsai@itri.org.tw



Main Products / Services / Pipelines & Platforms

- Dental Products Combining the Integration of Software and Hardware
- Minimally Invasive Medical Devices
- Biomedical-Grade Collagen, Wound Care Dressings, Nano Dressings, Skin External Applications and Functional Cosmeceutical Products
- Artificial Joints, Trauma, Spine and Other Orthopedic Products
- In Vitro Diagnostic Products
- Pharmaceutical Products
- Dietary Supplements
- Ophthalmic Femtosecond Laser Surgical Instruments
- Biomedical Image Detection and Intelligent Image Monitoring
- TFT X-ray Sensor

Business Interests

Collaborative R&D, CDMO

Contact Information

Name Mr. Wang, Young-Her
Position Section Chief
Tel +886 (6) 505 1001 Ext. 2520
Email beaniris@stsp.gov.tw



Main Pipelines & Platforms

As Taiwan's startup ecosystem is on the upward trajectory, gaining recognition and achieving good performances in the international arena, the National Development Council of Taiwan and the Taiwan startup community jointly created Startup Island TAIWAN.

- The Taiwan-Berkeley Health Innovation Accelerator Program is a partnership between Berkeley Public Health, the National Development Council of Taiwan, and the national startup brand of Taiwan, Startup Island TAIWAN.
- The program supports an annual cohort of startups from Taiwan who are seeking to bring their health innovations to the U.S. market and offers them access to the innovative healthcare opportunities in the Bay Area.
- The startups will undergo a 3-month intensive training on health policy and management of health innovations, as well as concierge access to a world-class network of expert advisers, mentors, and design consultants to help make their products more user-centered and market-ready for the U.S. market.

Business Interests

- Startup Island TAIWAN demonstrates the strong ambition and capabilities of Taiwan tech startups as well as their intention and ability to contribute to other startup ecosystems around the world. We hope to be your gateway to Taiwan's startup ecosystem.

Contact Information

Name Chiara Fu
Position Project Manager
Tel +886 (2) 3343 5456 Ext. 808
Email chiara@startupislandtaiwan.info



Main Products / Services / Pipelines & Platforms

- Biotech Industry Promotion.
- Assist companies with various requirements for setting up business in Taipei.
- Taipei City Government established ‘Taipei Municipal Self-Government Ordinance for Industrial Development’ , Small and Medium Enterprise of the Loan, and Young Entrepreneurs of the Loan.
- Taipei Bioinnovation Park: Industrial area for incubation centers, offices, R&D labs, and a prototyping factory, as well as multifunctional spaces for bio-tech companies.

Business Interests

- Welcome Int`l bio research unit and companies to land in Taipei.
- Well-equipped bio-cluster and IP protection enables you find partners in Taipei.

Contact Information

Name Sonia, Hsu
Position Researcher
Tel +886 (2) 2720 8889 Ext. 2090
Email ea-40177@gov.taipei



Main Services

- Taipei Exchange (TPEX) is a full-fledged exchange with a comprehensive suite of services with listing and trading platforms for equity, derivatives and debt market.
- TPEX has been an official member of the World Federation of Exchanges (WFE) since 2011 and joined ICMA as a full member in 2021. TPEX was recognized by the World Bank as one of the most successful SME exchanges in the world.
- More than 2,400 public companies have gained access to the capital market through TPEX. Prominent Electronics and Biotech groups consist of complete industrial clusters of firms operating in various sub-sectors. Over 65% of TPEX-listed firms are in Electronics and Biotech industries.
- TPEX provides a tiered structure, which ranges from the micro-enterprise supporting Go Incubation Board for Startup and Acceleration Firms (GISA), to the Emerging Stock Market (ESM) for pre-IPO companies, and on to the Mainboard (MB) for trading more established companies.
- In support of the innovative industry, TPEX has launched a new stock board named the Pioneer Stock Board (PSB) in Q3 2021. PSB has formed the ESM together with the existing Emerging Stock Board (ESB).
- TPEX launched the Sustainability-Linked Bond (SLB) in July 2022 to help issuers raising long-term and stable fund; thus, Taipei Exchange has successfully consolidated the regulations of Green Bonds, Sustainability Bonds, Social Bonds and Sustainability-Linked Bonds to launch a sustainable bond market exclusively for ESG concept bonds.

Business Interests

TPEX aims to attract issuers to list securities, providing investors with a fair, transparent, and efficient market.

Contact Information

Name Hui Ling Wei
Position Manager, Listing Examination Department
Tel +886 (2) 2366 6017
Email wlh@tpex.org.tw



Main Products / Services / Pipelines & Platforms

- Promoting the interests of our members
- Promoting international exchange and cooperation
- Promoting communication between government and industry
- Cultivating biotechnology industry talent
- Encouraging outstanding performance and innovation

Business Interests

BIO Asia–Taiwan

Asia's largest bioindustry-focused gathering, BIO Asia–Taiwan 2023, will be held July 26th to 30th, 2023, in Taipei, Taiwan. Co-organized by BIO (US-based global Biotechnology Innovation Organization) and Taiwan BIO (Taiwan Bio Industry Organization), executives, researchers and investors from North America, Europe, and Asia will come together to explore opportunities within Asia's thriving biotech sector.

Event site: <https://bioasiataiwan.com/en>

Contact Information

Name Mia Tsai
Position Marketing Specialist
Tel +886 (2) 2783 6028 Ext.13
Email mia@taiwanbio.org.tw



Main Services

Founded in 1970, TAITRA is Taiwan's foremost nonprofit trade promoting organization. Sponsored by the government and industry organizations, TAITRA assists enterprises to expand their global reach. Headquartered in Taipei, TAITRA has a team of 1,300 specialists and operates 5 local offices in Taoyuan, Hsinchu, Taichung, Tainan and Kaohsiung as well as 60+ branches worldwide. Together with Taipei World Trade Center (TWTC) and Taiwan Trade Center (TTC), TAITRA has formed a global network dedicated to promoting world trade.

- To assist Taiwanese businesses in developing international market.
- To collaborate closely with Taiwanese government in trade policy implementation.
- To provide business consultation service and connect international firms with Taiwanese partners.
- To assume the role of “Smart Integrator” - complement government policies, facilitate industry needs and develop new business opportunities around the world.

Business Interests

- Customized Sourcing Service
- Trade Shows & Events
- Find Products & Suppliers
- Global Network

Contact Information

Tel +886 (2) 2725 5200
Email taitra@taitra.org.tw



Company Description

- The Taiwan Stock Exchange (the “TWSE”) started operations on February 9, 1962. The TWSE is not only responsible for operating and advancing the domestic securities market, but also provides comprehensive services to the stock market.
- The TWSE is dedicated to assisting companies to list on the capital market, raising funds and expanding their operational scale. In 2021, the TWSE has launched a new trading platform “Taiwan Innovation Board (‘TIB’),” to make it easier for innovative enterprises to raise funds in capital market. The TWSE is looking forward to more applications from innovative enterprises from Taiwan and abroad.

Contact Information

Name Kuo, Nai-Yu
Position Associate, Foreign Listing Department
Tel +886 (2) 8101 3627
Email 1210@twse.com.tw



臺灣大學系統科研產業化平台 Global Industry Platform of NTU System



Global Industry Platform of NTU System



The Global Industry Platform of NTU System consists of Taiwan's leading comprehensive universities, including National Taiwan University, National Taiwan University of Science & Technology, National Taiwan Normal University, Chang Gung University, and Ming Chi University of Technology. Led by experienced professionals from diverse backgrounds, the platform provides enterprise members with the one-stop and tailored-made consulting service for facing future challenges. Inquiries about the following services as well as academia-academia collaborations and others are welcome.



National Taiwan University

Founded in 1928, National Taiwan University is located in Taipei, Taiwan, with a reputation for academic and research excellence. It consists of 16 colleges, 146 graduate institutes, 54 research institutes, and 1 affiliated hospital. It is consistently ranked as one of the best universities in Asia and has a diverse body of local and international students. Through education, research, and innovation, NTU is committed to cultivating talents and solutions for a better world.



Services:

<p>Tailored Made Industry-Academia Collaborations</p> 	<p>Talent Cultivation & Matchmaking</p> 	<p>New Venture Incubation & Development</p> 	
<p>Worldwide Business Opportunities</p> 	<p>Technical & Investment Consulting</p> 	<p>Databases</p> 	<p>Laboratory Facilities</p> 


Contact

Industry Liaison Office, National Taiwan University
Tel: +886-2-3366-8286 E-Mail: ntuilo@ntu.edu.tw



Your Best Partner in Asia

One-Stop-Shop for Taiwan's Biomedical Industry

 Biotechnology and Pharmaceutical Industries Promotion Office, MOEA

Tel: +886 (2) 2655 8135

E-Mail: services@biopharm.org.tw

Web: <https://www.biopharm.org.tw>



Delegation
Website



BPIPO
Website